Boston Scientific Corp. (BSX) Valuation
Historical valuation analysis based on 1281 data points (2021-09-10 to 2026-10-16)
Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtrati...
Boston Scientific Corp. (BSX) currently trades at a P/E ratio of 17.51 (historical range: 16.40–122.28, median: 70.31), placing it at the 2th percentile — cheap relative to its history, P/S ratio of 3.06 (range: 2.87–10.36, 2th percentile — cheap relative to its history), EV/EBITDA of 18.40 (range: 17.26–148.58, 3th percentile).
Over the historical period (2021-09-10 to 2026-10-16), Boston Scientific Corp.'s P/E ratio has contracted by 29% over the observed period (from an average of 80.3 to 57.1).
Boston Scientific Corp. trades well below its historical valuation range across most metrics.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|---|---|---|---|
| P/E Ratio | 17.51 | 70.31 | 2th | cheap relative to its history |
| P/S Ratio | 3.06 | 5.70 | 2th | cheap relative to its history |
| EV/EBITDA | 18.40 | 49.69 | 3th | cheap relative to its history |
| FCF Yield | 5.63% | 1.83% | 97th | cheap relative to its history |
Boston Scientific Corp. (BSX) Valuation & P/E History
Boston Scientific Corp. (BSX) is a US-listed stock operating in the Healthcare sector, specifically the Medical Devices industry currently trading at $44.20 with a market capitalization of $64.1 billion. This page provides historical valuation analysis for BSX based on 1281 data points covering 2021-09-10 to 2026-10-16. The P/E ratio of 17.51 is below the historical median of 70.31, placing BSX at the 2th percentile of its valuation range. The P/S ratio of 3.06 compares to a median of 5.70.
BSX Valuation Metrics & Historical Range
The valuation table above shows Boston Scientific Corp.'s current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether BSX is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests BSX is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Boston Scientific Corp..
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is BSX Overvalued or Undervalued?
Boston Scientific Corp. trades well below its historical valuation range across most metrics. The overall valuation percentile of 2 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive BSX is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full BSX analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.BSX trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.